Page last updated: 2024-11-13
triletide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
triletide: thromboxane A2 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21114913 |
| SCHEMBL ID | 9551361 |
| MeSH ID | M0119781 |
Synonyms (22)
| Synonym |
|---|
| 62087-96-1 |
| triletide |
| methyl (2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1h-imidazol-5-yl)propanoate |
| triletida [spanish] |
| triletide [inn] |
| l-histidine, n-(n-(n-acetyl-l-phenylalanyl)-l-phenylalanyl)-, methyl ester |
| 50q6li773l , |
| einecs 263-401-1 |
| n-(n-(n-acetyl-3-phenyl-l-alanyl)-3-phenyl-l-alanyl)-l-histidine, methyl ester |
| unii-50q6li773l |
| triletidum |
| triletidum [latin] |
| triletida |
| triletide [mart.] |
| SCHEMBL9551361 |
| ac-phe-phe-his-ome |
| methyl acetyl-l-phenylalanyl-l-phenylalanyl-l-histidinate |
| (s)-methyl 2-((s)-2-((s)-2-acetamido-3-phenylpropanamido)-3-phenylpropanamido)-3-(1h-imidazol-4-yl)propanoate |
| Q27260813 |
| methyl (2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1h-imidazol-5-yl)propanoate |
| DTXSID801174335 |
| n-acetyl-l-phenylalanyl-l-phenylalanyl-l-histidine methyl ester |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Metabolization to desmethyl, desacetyl, desmethyl-desacetyl and hydroxylated derivatives plays a major role in the biotransformation of the drug and thus in its disappearance from blood, the distribution half-life being about 1 hour." | ( Preliminary human pharmacokinetics of triletide. Repossini, L, 1985) | 0.54 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Elimination half-life ranged about 5 hours, thus suggesting a dosage schedule of 3-times daily for loading, while for maintenance a twice-daily schedule appears also suitable." | ( Preliminary human pharmacokinetics of triletide. Repossini, L, 1985) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.51) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (63.64%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (36.36%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||